Linomide improves the effect of interstitial laser thermotherapy in a rat liver tumour model.
OBJECTIVE
The aim of this study was to investigate if Linomide affects growth and spread of a rat liver tumour when given alone and in combination with interstitial laser thermotherapy (ILT).


METHODS
Experiments were performed in Wistar rats using a dimethyl-hydrazine-induced adenocarcinoma implanted into the left lateral lobe of the liver. The rats were randomised to one of the following groups: a) ILT and Linomide, b) ILT only, c) sham ILT, d) Linomide only, or e) control. ILT was intentionally suboptimal. Linomide (100 mg/kg/day) was given in the drinking water from the start of treatment for five days. ED1, ED2 macrophages and v Willebrand (factor VIII) were determined by an immunohistochemical technique.


RESULTS
Linomide reduced viable liver tumour volume both when it was given alone (p < 0.01) and when combined with ILT (p < 0.05), whereas it lowered intraperitoneal spread in ILT-treated rats alone. Six days after ILT, there was a reduction in the number of newly-recruited macrophages and blood vessels in the viable tumour tissue in rats receiving Linomide.


CONCLUSIONS
Linomide reduced the growth of an adenocarcinoma transplanted into rat liver, when given alone or combined with laser thermotherapy and reduced the spread of tumour in laser-treated rats. The effects of Linomide in laser-treated rats appeared, at least in part, to be due to a reduction in newly-formed vessels, which might have been secondary to a reduced number of tumour-associated macrophages.
Ivarsson
Kjell
K
Department of Surgery, Lund University, SE-22185 Lund, Sweden.
Sturesson
Christian
C
Stenram
Unne
U
Tranberg
Karl-Göran
KG
D000230:Adenocarcinoma / Q000098:blood supply / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000473:pathology; D003131:Combined Modality Therapy; D004354:Drug Screening Assays, Antitumor; D006912:Hydroxyquinolines / Q000494:pharmacology / Q000627:therapeutic use*; D006979:Hyperthermia, Induced; D007834:Lasers; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy; D008264:Macrophages / Q000473:pathology; D008297:Male; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D000276:Adjuvants, Immunologic; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D006912:Hydroxyquinolines; C045282:roquinimex